Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

Fig. 4

Tumor responses and patient outcomes during the course of this study: A Waterfall plot of CT scan findings according to modified Response Evaluation Criteria in Solid Tumors 1.1. B Swimmer plot of time on study treatment, response status, and survival. C Spider plot of tumor trajectories. D Kaplan–Meier (KM) curve of progression-free survival (PFS)

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us